FMC regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of xxx used to treat xxx. ==Regimen== {{chemo|x|xx}} {{chemo|x|xx}}...") |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}} FCM regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of | {{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[cyclophosphamide]] and [[mitoxantrone]] used in the treatment of resistant or relapsed [[chronic lymphocytic leukaemia]]. | ||
<ref name="pmid12472576">{{cite journal| author=Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N et al.| title=Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. | journal=Br J Haematol | year= 2002 | volume= 119 | issue= 4 | pages= 976-84 | pmid=12472576 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12472576 }} </ref> | |||
==Regimen== | ==Regimen== | ||
{{chemo| | {{chemo|F|Fludarabine}} | ||
{{chemo| | {{chemo|C|Cyclophosphamide}} | ||
{{chemo| | {{chemo|M|Mitoxantrone}} | ||
==Indications== | ==Indications== | ||
*[[Chronic lymphocytic leukaemia]]<ref name="pmid12472576">{{cite journal| author=Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N et al.| title=Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. | journal=Br J Haematol | year= 2002 | volume= 119 | issue= 4 | pages= 976-84 | pmid=12472576 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12472576 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 16:24, 31 March 2015
|
WikiDoc Resources for FMC regimen |
|
Articles |
|---|
|
Most recent articles on FMC regimen Most cited articles on FMC regimen |
|
Media |
|
Powerpoint slides on FMC regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FMC regimen at Clinical Trials.gov Clinical Trials on FMC regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FMC regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FMC regimen Discussion groups on FMC regimen Patient Handouts on FMC regimen Directions to Hospitals Treating FMC regimen Risk calculators and risk factors for FMC regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FMC regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: FCM regimen
Overview
FMC regimen refers to a regimen consisting of fludarabine, cyclophosphamide and mitoxantrone used in the treatment of resistant or relapsed chronic lymphocytic leukaemia. [1]
Regimen
FFludarabine
CCyclophosphamide
MMitoxantrone
Indications
References
- ↑ 1.0 1.1 Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N; et al. (2002). "Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia". Br J Haematol. 119 (4): 976–84. PMID 12472576.